

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Single Technology Appraisal


# Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy ID4070

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company         BeiGene (tislelizumab)         Patient/carer groups         Black Health Agency for Equality         Cancer 52         Cancer Black Care         Cancer Equality         GIST Cancer UK         GUTS UK         Heartburn Cancer UK         Helen Rollason Cancer Charity         Independent Cancer Patients Voice         Macmillan Cancer Support         Maggie's Centres         Marie Curie         Ochre         Oesophageal Patients Association         OG Support formerly Together Support Group         PAWS GIST Clinic         South Asian Health Foundation         Specialised Healthcare Alliance         Tenovus Cancer Care         Healthcare professional groups         Association of Anaesthetists         Association of Surgeons of Great Britain and Ireland	General         • All Wales Therapeutics and Toxicology Centre         • Allied Health Professionals Federation         • Board of Community Health Councils in Wales         • British National Formulary         • Care Quality Commission         • Department of Health - Northern Ireland         • Healthcare Improvement Scotland         • Medicines and Healthcare products Regulatory Agency         • National Association of Primary Care         • National Pharmacy Association         • NHS Confederation         • Scottish Medicines Consortium         • Welsh Government         • Welsh Health Specialised Services Committee         •         •         • Accord Healthcare (docetaxel, irinotecan, paclitaxel)         • Bristol Myers Squibb Pharmaceuticals (nivolumab, paclitaxel)         • Celgene (paclitaxel)         • Genzyme Therapeutics (docetaxel)         • Hospira UK (docetaxel, irinotecan, paclitaxel)         • Inceptua (paclitaxel)
<ul> <li>Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland</li> <li>British Association of Surgical Oncology</li> <li>British Geriatrics Society</li> </ul>	<ul> <li>Medac (docetaxel, irinotecan, paclitaxel)</li> <li>Pfizer (irinotecan)</li> <li>Ranbaxy UK limited a Sun Pharmaceutical Company (irinotecan)</li> </ul>

Provisional stakeholder list for the evaluation of tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy ID4070 Issue date: July 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>British Institute of Radiology</li> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> <li>British Society of Gastroenterology</li> <li>Cancer Research UK</li> <li>Primary Care Society for Gastroenterology</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal College of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul>	<ul> <li>Seacross Pharmaceuticals (docetaxel, irinotecan)</li> <li>Servier Laboratories (irinotecan)</li> <li><u>Relevant research groups</u></li> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li><u>Associated Public Health groups</u></li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


# **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy ID4070 Issue date: July 2024 © National Institute for Health and Care Excellence 2024. All rights reserved. 2 of 3



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.